The impact of aging on chemotherapy

Clinical Lung Cancer

Volumn 5, Issue 4, 2004, Pages 243-244

  Malik, Shakun M ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; AGING; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CARDIOTOXICITY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; HUMAN; INFECTION; LUNG CANCER; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; NOTE; PATIENT COMPLIANCE; STATISTICAL SIGNIFICANCE;

EID: 1542360631     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-7304(11)70345-X     Document Type: Note

References (17)

1. Lee-Chiong TL Jr, Matthay RA. Lung cancer in the elderly patient. Clin Chest Med 1993; 14:453-478.
2. Crook A, Duffy A, Girling DJ, et al. Survey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales. Eur Respir J 1997; 10: 1552-1558.
3. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest 2000; 117:1239-1246.
4. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061-2067.
5. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: J Natl Cancer Inst 2002; 94:173-181.
6. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986; 4:702-709.
7. Jiroutek M, Johnson D, Blum R, et al. Prognostic factors in advanced non-small cell lung cancer (NSCLC): analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981-1992. Proc Am Soc Clin Oncol 1998; 17:461a (Abstract #1774).
8. Liu G, Franssen E, Fitch MI, et al. Patient preference for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15:110-115.
9. Partridge AH, Avorn J, Wang PS, et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002; 94:652-661.
10. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999; 91:66-72.
11. Crawford J, O'Rourke M, Schiller JH, et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small cell lung cancer. J Clin Oncol 1996; 14:2774-2784.
12. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer, the Multicenter Italian Lung Cancer in Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95:362-372.
13. Marty M, Fumoleau P, Adenis A, et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001; 12:1643-1649.
14. Variol P, Bonneterre J, Marty M, et al. Pharmacokinetic/pharmacodynamic relationships of IV and oral navelbine in phase I patients. Proc Am Soc Clin Oncol 2001; 20:110a (Abstract #435).
15. Puozzo C, Zorza G, Guimbaud R, et al. Metabolism of vinorelbine in human clinical application. Proc Am Soc Cancer Res 2000; 41:280 (Abstract #1781).
16. Puozzo C, Gridelli C. Non-small-cell lung cancer in elderly patients: influence of age on vinorelbine oral pharmacokintics. Clin Lung Cancer 2004; 5:237-242.
17. Peck C, Barr W, Benet L, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics and toxikinetics in rational drug development. Clin Pharmacol Ther 1992; 51:465-473.